Connect to other sites within the UBM Medica Network
Early Trial Finds Immunotherapy Effective in Liver Cancer
Results from a phase I/II study suggest that the immunotherapy nivolumab is safe and effective in advanced hepatocellular carcinoma (HCC).
Aflatoxin Linked to Risk of Gallbladder Cancer
Aflatoxin, a naturally occurring toxin produced by certain types of molds, has been found to be associated with an increased risk of gallbladder cancer.
Statins Linked With Reduced Liver Cancer in Low-Rate Areas
Current use of statins was associated with about a 50% decreased risk for liver cancer, according to results of a study looking at data from the United Kingdom.
RT Effective for Palliation of Bone Metastases From HCC
A recent study found that radiation therapy was effective for the palliation of painful spinal metastases in patients with hepatocellular carcinoma.
Baseline AFP Levels Affect Ramucirumab Benefit in HCC
Hepatocellular carcinoma patients with baseline alpha-fetoprotein (AFP) levels greater than 400 ng/mL may derive greater benefit from second-line ramucirumab.
Adding Erlotinib in HCC Fails to Improve Outcomes
In a phase III trial, erlotinib performed no better than placebo when added to sorafenib in treatment-naive patients with advanced hepatocellular carcinoma.
Cediranib Improves Response Rate, Not PFS in Biliary Tract Cancer
The addition of cediranib to treatment with cisplatin/gemcitabine did not improve progression-free survival in patients with advanced biliary tract cancer, according to the results of the phase II ABC-03 trial.
By clicking Accept, you agree to become a member of the UBM Medica Community.